Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Department of Surgery, Isahaya General Hospital, 24-1 Isahaya, Nagasaki, 854-8501, Japan.
Langenbecks Arch Surg. 2024 Jan 6;409(1):28. doi: 10.1007/s00423-023-03222-7.
Positive pathologic lymph nodes in colorectal cancer represent an important prognostic indicator. Whether lymph node distribution or the number of metastatic nodes is more strongly associated with survival prediction remains controversial.
Among 3449 colorectal cancer surgeries performed at Nagasaki University Hospital and five affiliated institutions from April 2016 to March 2022, we investigated 604 patients who underwent laparoscopic radical resection and were diagnosed with pathological stage III cancer. Patients were divided into two groups according to whether they had central vessel metastasis (LND3 group, n=42) or not (LND1/2 group, n=562). After adjusting for background factors using propensity score matching, the LND3 group included 42 patients and the LND1/2 group included 40 patients. Patient background characteristics and prognosis were compared between these two groups.
Before matching, frequencies of right-side colon cancer (64.3% vs 38.1%, p=0.001), multivisceral resection (11.9% vs 4.4%, p=0.039), clinical N2 status (40.5% vs 22.6%, p=0.032), and pathological N2 (73.8% vs 22.6%, p<0.001) were all greater, and the number of lymph nodes retrieved was higher (24 vs 19, p=0.042) in the LND3 group. After matching, no differences in any clinical factors were evident between groups. Five-year RFS (44.8% vs 77.1%, p=0.004) and OS (43.1% vs 83.2%, p<0.001) were worse in the LND3 group. Adjuvant chemotherapy improved RFS (adjuvant chemotherapy (+) vs adjuvant chemotherapy (-): 62.1% vs 27.7%, p=0.047) in the LND3 group.
LND3-positive patients show poorer prognosis than LND1/2 patients and should be treated with an appropriate perioperative treatment strategy.
结直肠癌中阳性病理淋巴结是一个重要的预后指标。淋巴结分布或转移淋巴结数量与生存预测的关系仍存在争议。
在 2016 年 4 月至 2022 年 3 月期间,我们对在长崎大学医院和五家附属医院接受腹腔镜根治性切除术并被诊断为病理 III 期癌症的 3449 例结直肠癌患者中的 604 例患者进行了研究。根据是否存在中央血管转移(LND3 组,n=42)将患者分为两组。对背景因素使用倾向评分匹配后,LND3 组包括 42 例患者,LND1/2 组包括 40 例患者。比较两组患者的背景特征和预后。
在匹配前,右半结肠癌(64.3% vs 38.1%,p=0.001)、多脏器切除(11.9% vs 4.4%,p=0.039)、临床 N2 期(40.5% vs 22.6%,p=0.032)和病理 N2 期(73.8% vs 22.6%,p<0.001)的比例较高,LND3 组的淋巴结检出数较高(24 枚 vs 19 枚,p=0.042)。匹配后,两组间无任何临床因素差异。LND3 组的 5 年 RFS(44.8% vs 77.1%,p=0.004)和 OS(43.1% vs 83.2%,p<0.001)均较差。辅助化疗改善了 LND3 组的 RFS(辅助化疗(+)vs 辅助化疗(-):62.1% vs 27.7%,p=0.047)。
LND3 阳性患者的预后较 LND1/2 患者差,应采用适当的围手术期治疗策略。